Diabetes Care, Vol 15, Issue 5 666-692, Copyright © 1992 by American Diabetes Association

ARTICLES

Biosynthetic human proinsulin. Review of chemistry, in vitro and in vivo receptor binding, animal and human pharmacology studies, and clinical trial experience

JA Galloway, SA Hooper, CT Spradlin, DC Howey, BH Frank, RR Bowsher and JH Anderson
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285.

OBJECTIVE--To describe the rationale for the preclinical and clinical developmental course of human proinsulin (HPI), the second product after human insulin for the treatment of diabetes mellitus to be manufactured by DNA technology. RESEARCH DESIGN AND METHODS--The relevant and available published and unpublished preclinical and clinical information generated on pork proinsulin and human proinsulin has been integrated to demonstrate how certain clinically attractive features of pork proinsulin (a soluble intermediate-acting and possibly hepatospecific insulin agonist) led to the development of HPI. RESULTS--Clinical pharmacology studies demonstrated that HPI was definitely, although marginally, hepatospecific. More striking was the finding that the intrasubject/patient coefficient of variation of response to HPI was significantly less than that observed with NPH insulin. However, the fact that unique efficacy in controlled multicenter studies was not demonstrated suggested that these pharmacological features were not translated into clinical benefit. In one multicenter new patient study there were six myocardial infarctions, including two deaths, in patients treated for greater than or equal to 1 yr with HPI and none in the control group. CONCLUSIONS--To obtain an independent review of the risks and benefits of HPI, in February 1988, Lilly convened a consultant group that examined all relevant information on HPI available. These experts shared our concerns about the safety of HPI in light of the failure to demonstrate unique efficacy. Accordingly, clinical trials with HPI were suspended in February 1988. Experience with HPI demonstrates the challenge associated with the development of new drugs in general and insulin agonists in particular.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				D.-J. Kim and E. Barrett-Connor Association of serum proinsulin with hormone replacement therapy in nondiabetic older women: the rancho bernardo study. Diabetes Care, March 1, 2006; 29(3): 618 - 624. [Abstract] [Full Text] [PDF]

				E. Ingelsson, J. Arnlov, J. Sundstrom, B. Zethelius, B. Vessby, and L. Lind Novel Metabolic Risk Factors for Heart Failure J. Am. Coll. Cardiol., December 6, 2005; 46(11): 2054 - 2060. [Abstract] [Full Text] [PDF]

				M. Alssema, J. M. Dekker, G. Nijpels, C. D.A. Stehouwer, L. M. Bouter, and R. J. Heine Proinsulin Concentration Is an Independent Predictor of All-Cause and Cardiovascular Mortality: An 11-year follow-up of the Hoorn Study Diabetes Care, April 1, 2005; 28(4): 860 - 865. [Abstract] [Full Text] [PDF]

				A. Pfutzner, T. Kunt, C. Hohberg, A. Mondok, S. Pahler, T. Konrad, G. Lubben, and T. Forst Fasting Intact Proinsulin Is a Highly Specific Predictor of Insulin Resistance in Type 2 Diabetes Diabetes Care, March 1, 2004; 27(3): 682 - 687. [Abstract] [Full Text] [PDF]

				B. Desbuquois, G. Chauvet, M. Kouach, and F. Authier Cell Itinerary and Metabolic Fate of Proinsulin in Rat Liver: In Vivo and in Vitro Studies Endocrinology, December 1, 2003; 144(12): 5308 - 5321. [Abstract] [Full Text] [PDF]

				A. Tura, G. Pacini, A. Kautzky-Willer, B. Ludvik, R. Prager, and K. Thomaseth Basal and dynamic proinsulin-insulin relationship to assess {beta}-cell function during OGTT in metabolic disorders Am J Physiol Endocrinol Metab, July 1, 2003; 285(1): E155 - E162. [Abstract] [Full Text] [PDF]

				C. W. Chia and C. D. Saudek The Diagnosis of Fasting Hypoglycemia Due to an Islet-Cell Tumor Obscured by a Highly Specific Insulin Assay J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1464 - 1467. [Abstract] [Full Text] [PDF]

				Z. Vajo, J. Fawcett, and W. C. Duckworth Recombinant DNA Technology in the Treatment of Diabetes: Insulin Analogs Endocr. Rev., October 1, 2001; 22(5): 706 - 717. [Abstract] [Full Text] [PDF]

				A. J.G. Hanley, G. McKeown-Eyssen, S. B. Harris, R. A. Hegele, T. M.S. Wolever, J. Kwan, P. W. Connelly, and B. Zinman Cross-Sectional and Prospective Associations Between Proinsulin and Cardiovascular Disease Risk Factors in a Population Experiencing Rapid Cultural Transition Diabetes Care, July 1, 2001; 24(7): 1240 - 1247. [Abstract] [Full Text] [PDF]

				L. Bokemark, J. Wikstrand, and B. Fagerberg Intact Insulin, Insulin Propeptides, and Intima-media Thickness in the Femoral Artery in 58-year-old Clinically Healthy Men: The Atherosclerosis and Insulin Resistance Study Angiology, April 1, 2001; 52(4): 237 - 245. [Abstract] [PDF]

				M. Ebinger, D. R. Jehle, R. D. Fussgaenger, H. C. Fehmann, and P. M. Jehle Glucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes Am J Physiol Endocrinol Metab, July 1, 2000; 279(1): E88 - E94. [Abstract] [Full Text] [PDF]

				Z. Vajo and W. C. Duckworth Genetically Engineered Insulin Analogs: Diabetes in the New Millenium Pharmacol. Rev., March 1, 2000; 52(1): 1 - 10. [Abstract] [Full Text] [PDF]

				D. K. Short, S. Okada, K. Yamauchi, and J. E. Pessin Adenovirus-mediated transfer of a modified human proinsulin gene reverses hyperglycemia in diabetic mice Am J Physiol Endocrinol Metab, November 1, 1998; 275(5): E748 - E756. [Abstract] [Full Text] [PDF]

				T. K. Nordt, H. Sawa, S. Fujii, and B. E. Sobel Induction of Plasminogen Activator Inhibitor Type-1 (PAI-1) by Proinsulin and Insulin In Vivo Circulation, February 1, 1995; 91(3): 764 - 770. [Abstract] [Full Text]

				B. Zethelius, L. Byberg, C. N. Hales, H. Lithell, and C. Berne Proinsulin Is an Independent Predictor of Coronary Heart Disease: Report From a 27-Year Follow-Up Study Circulation, May 7, 2002; 105(18): 2153 - 2158. [Abstract] [Full Text] [PDF]